UK-based Enterprise Therapeutics, which is developing inhaled ENaC blockers for the treatment of cystic fibrosis and other respiratory conditions, has named former Insmed Executive VP of Development and Chief Medical Officer Renu Gupta as the company’s new CMO. Enterprise also announced the appointment of Janet Hammond, currently Chief Development Officer at Atea Pharmaceuticals, as a non-executive director.
Gupta was most recently CMO at Promedior and previously held roles at number of companies, including Novartis, Covance, and Bristol-Myers Squibb (BMS). She has also served as a board member at a number of companies, including Breath Therapeutics.
According to the Enterprise web site, the company is developing both nebulized and dry powder formulations of ETD001 and expects to begin a Phase 2a trial in CF patients this summer. Earlier this year, Enterprise raised £26 million in a Series B financing to support the upcoming trial.
Enterprise Therapeutics CEO John Ford commented, “We are delighted to welcome Renu as CMO and Janet to the board. Renu’s successful track record in developing innovative respiratory medicines will be a great asset to the team, while Janet’s extensive experience in driving late-stage clinical development programs will be an invaluable addition to the board. Both appointments substantially strengthen our team as we work towards delivering clinical proof of concept for our lead asset ETD001, taking us a step closer to providing an effective therapy for people with cystic fibrosis not benefitting from CFTR modulators.”
Gupta said, “Enterprise Therapeutics’ development program shows impressive dedication and great promise for the treatment of those people with cystic fibrosis not currently served by existing therapies. I am excited to join the company, and look forward to working with John, Janet, and the rest of the team as we progress through Phase 2 trials.”
Read the Enterprise Therapeutics press release.
